Botulism

Skin Tightening, Botox and Lip Fillers by Skinsation LA: Helping Clients Feel Confident in Their Own Skin

Retrieved on: 
Thursday, July 15, 2021
Drugs, Health care, Clinical medicine, Plastic surgery, Botulinum toxin, Botulism, Neurotoxins, Facial, Spa

Luckily, there are several effective beauty treatments that can help you to feel and look your best.

Key Points: 
  • Luckily, there are several effective beauty treatments that can help you to feel and look your best.
  • Skin Tightening, Botox and Lip Fillers by Skinsation LA is a pioneering medical and facial spa Los Angeles .
  • The entire spa is designed with both health and relaxation in mind, so clients can feel comfortable and less anxious while attending appointments.
  • To learn more about Botox, lip fillers, injectables, and more, visit the website at https://www.skinsationla.com/ , where you can also find directions from Los Angeles .

Global Botulinum Toxin Market Witnessing Speedy Recovery Following 2020 Slump - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Cosmetics, Retail, Drugs, Toxins, Botulinum toxin, Botulism, Neurotoxins

The "Botulinum Toxin - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Botulinum Toxin - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Botulinum Toxin to Reach $6.8 Billion
    The global market for Botulinum Toxin is projected to reach US$6.8 billion by the year 2027, trailing a post COVID-19 CAGR of 7.2% over the analysis period 2020 through 2027.
  • Botulinum Toxin market will go from a -8.6% slump in 2020 to a speedy recovery of 4.7% in 2021.
  • The market for long has been characterized by huge unmet medical needs and the ensuing strong off-label aesthetic and therapeutic uses of botulinum toxin.

Global Botulinum Toxin Market to Reach $7.9 Billion by 2026

Retrieved on: 
Tuesday, June 29, 2021
Drugs, Botulism, Toxins, Botulinum toxin, Neurotoxins

SAN FRANCISCO, June 29, 2021 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Botulinum Toxin - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, June 29, 2021 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Botulinum Toxin - Global Market Trajectory & Analytics" .
  • Amid the COVID-19 crisis, the global market for Botulinum Toxin estimated at US$4.9 Billion in the year 2020, is projected to reach a revised size of US$7.9 Billion by 2026, growing at a CAGR of 8.2% over the analysis period.
  • The U.S. Market is Estimated at $3.1 Billion in 2021, While China is Forecast to Reach $665 Million by 2026
    The Botulinum Toxin market in the U.S. is estimated at US$3.1 Billion in the year 2021.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Teijin Receives Additional Approval in Japan for Merz’s Xeomin® Botulinum Toxin Type A

Retrieved on: 
Wednesday, June 23, 2021
Biotechnology, Medical devices, Health, Pharmaceutical, Clinical trials, Drugs, Botulism, Gram-positive bacteria, Medical specialties, Clinical medicine, Botulinum toxin, Neurotoxins, Toxins, Merz Pharma, Clostridium botulinum, Merz, Clostridium, Xeomin®, Merz Therapeutics, the Teijin Group, XEOMIN®, MERZ THERAPEUTICS, THE TEIJIN GROUP

Dr. Stefan Albrecht, Senior Vice President Merz Therapeutics Global R&D: This label extension in Japan is another outstanding example for the benefits Xeomin offers to many post-stroke spasticity patients.

Key Points: 
  • Dr. Stefan Albrecht, Senior Vice President Merz Therapeutics Global R&D: This label extension in Japan is another outstanding example for the benefits Xeomin offers to many post-stroke spasticity patients.
  • The highly purified neurotoxin, the only active ingredient in Xeomin, is made by removing complexing proteins from botulinum toxin type A, which is produced by Clostridium botulinum, using purification technology developed by Merz Pharma GmbH & Co. KGaA.
  • Teijin Pharma signed an exclusive license and co-development agreement for Xeomin in Japan with Merz in 2017, and launched exclusive sales of Xeomin in December 2020 after receiving approval granted by Japans Ministry of Health, Labor and Welfare (MHLW).
  • The newly received additional approval for partial changes in the obtained approval based on the phase-III clinical trials conducted by Merz in Japan.

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

Retrieved on: 
Friday, June 11, 2021
Biotechnology, Pharmaceutical, Health, Medical devices, Drugs, Health, Botulism, Branches of biology, Plastic surgery, Botulinum toxin, Neurotoxins, Wrinkle, Galderma, Bont, Galderma, Alluzience® (liquid botulinum toxin type A), GALDERMA, ALLUZIENCE® (LIQUID BOTULINUM TOXIN TYPE A)

Galderma today announced that Alluzience has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe.

Key Points: 
  • Galderma today announced that Alluzience has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe.
  • Like many aspects of physical appearance, glabellar lines can have a significant impact on patients confidence and wellbeing.
  • Ive heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues.
  • Alluzience (liquid botulinum toxin type A) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe.

AEON Biopharma Appoints Dr. Chad K. Oh as Chief Medical Officer to Lead Clinical Development of ABP-450 Across Several Therapeutic Indications

Retrieved on: 
Wednesday, June 9, 2021
Drugs, Botulism, Medicine, Toxins, Botulinum toxin, Neurotoxins, Indication

We are excited to expand the management team with the addition of Dr. Oh as our Chief Medical Officer.

Key Points: 
  • We are excited to expand the management team with the addition of Dr. Oh as our Chief Medical Officer.
  • I am proud to join the AEON team, and plan to lead ABP-450s clinical development strategy with incredible passion and commitment as we look to make a difference in patients lives.
  • Before joining Weinberg Group, he was Vice President of Clinical Development at Revance Therapeutics, during which time he helped develop its botulinum toxin Type A for several therapeutic indications in the U.S.
  • The company continues to evaluate additional therapeutic indications for development based on a comprehensive product assessment process designed to identify those indications where it believes ABP-450 can attain clinical, regulatory, and commercial success.

Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign

Retrieved on: 
Tuesday, June 8, 2021
Drugs, Plastic surgery, Toxins, Botulinum toxin, Botulism, Neurotoxins, Allergan, Cosmetic

Each person's story and journey are different," says Carrie Strom, Senior Vice President, AbbVie and President, Global Allergan Aesthetics.

Key Points: 
  • Each person's story and journey are different," says Carrie Strom, Senior Vice President, AbbVie and President, Global Allergan Aesthetics.
  • These stories are authentic, honest, and relatable and reflect that a BOTOX Cosmetic patient is likely someone you know.
  • BOTOX Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX Cosmetic.
  • Department of Health and Human Services FDA Approval Letter for BOTOX Cosmetic for Glabellar Lines, 2002.

Revance to Participate in Upcoming Virtual Healthcare Conferences

Retrieved on: 
Wednesday, May 26, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Drugs, Toxins, Botulinum toxin, Botulism, Neurotoxins, Toxicology

The Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 1:40 p.m. PT / 4:40 p.m.

Key Points: 
  • The Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 1:40 p.m. PT / 4:40 p.m.
  • Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA.

Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection

Retrieved on: 
Wednesday, May 26, 2021
Cosmetics, Retail, FDA, Health, Pharmaceutical, Biotechnology, Drugs, Plastic surgery, Toxins, Neurotoxins, Botulinum toxin, Botulism, Branches of biology, Hyaluronic acid

Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection.

Key Points: 
  • Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection.
  • DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA.

Cosmopolitan Names Aerolase "Best Facial Laser" in Its Holy Grail Beauty Awards

Retrieved on: 
Tuesday, May 25, 2021
Drugs, Plastic surgery, Toxins, Botulinum toxin, Botulism, Neurotoxins, Dermatology, Toxicology

The Holy Grail Beauty Awards places Aerolase Neo Elite into an iconic group of global aesthetic brands, such as Botox, Juvedermand others, underlining Aerolase's best-in-class stature for aesthetic solutions.

Key Points: 
  • The Holy Grail Beauty Awards places Aerolase Neo Elite into an iconic group of global aesthetic brands, such as Botox, Juvedermand others, underlining Aerolase's best-in-class stature for aesthetic solutions.
  • Neo Elite improves 36 FDA-cleared face and body indications, delivering our unique No Skin Contact treatment, in high demand in a Covid environment.
  • Further hallmarks of Neo Elite include no pain, no anesthetics, no patient down time, and efficacy + safety on skin of color and tanned skin.
  • "In laser dermatology and aesthetics, the Neo Elite is proving to be what the iPhone has been to the modern smartphone.